DelveInsight’s “HR-positive/HER2-negative Breast Cancer Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the HR-positive/HER2-negative Breast Cancer pipeline landscapes. It comprises HR-positive/HER2-negative Breast Cancer pipeline drug profiles, including clinical and non-clinical stage products. It also includes the HR-positive/HER2-negative Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive HR-positive/HER2-negative Breast Cancer pipeline products.
Some of the key takeaways of the HR-positive/HER2-negative Breast Cancer Pipeline Report
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Jiangsu HengRui Medicine, Radius Pharmaceuticals, Immunomedics, Roche, Syndax Pharmaceuticals, Merck Sharp and Dohme, Merck Sharp and Dohme Corp./Eisai, Bayer, etc., are developing therapies for the treatment of HR-positive/HER2-negative Breast Cancer.
-
Emerging therapies such as SHR6390, Elacestrant (RAD1901), Sacituzumab govitecan, Ipatasertib and Venclexta, Entinostat, Pembrolizumab, Eribulin Mesylate, Radium-223 dichloride, are expected to have a significant impact on the HR-positive/HER2-negative Breast Cancer market in the coming years.
-
The postmenopausal breast cancer market size within the 7MM was found to be USD 6,315.1 million in 2018.
-
The HR-positive/HER2-negative Breast Cancer market size shall increase during the forecast period 2021–2030.
-
Among the 7MM, the US accounts for 80.51% USD of the HR-positive/HER2-negative Breast Cancer market size in 2018.
Get an overview of pipeline landscape @HR-positive/HER2-negative Breast Cancer Clinical Trials Analysis
HR-positive/HER2-negative breast cancer is the commonest carcinoma and also accounts for a better percentage of all breast cancers. HR-positive cancer is typically treated with hormone therapies or a combination of hormone therapies with targeted therapy to assist stop tumor growth.
HR-positive/HER2-negative Breast Cancer Emerging Drugs
-
SHR6390 by Jiangsu HengRui Medicine
-
Elacestrant (RAD1901) by Radius Pharmaceuticals
-
Sacituzumab govitecan by Immunomedics
-
Ipatasertib and Venclexta by Roche
-
Entinostat by Syndax Pharmaceuticals
-
Pembrolizumab by Merck Sharp and Dohme
-
Eribulin Mesylate by Merck Sharp and Dohme Corp./Eisai
-
Radium-223 dichloride by Bayer
-
And others.
Scope of HR-positive/HER2-negative Breast Cancer Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Jiangsu HengRui Medicine, Radius Pharmaceuticals, Immunomedics, Roche, Syndax Pharmaceuticals, Merck Sharp and Dohme, Merck Sharp and Dohme Corp./Eisai, Bayer, and others.
-
Pipeline Therapies: SHR6390, Elacestrant (RAD1901), Sacituzumab govitecan, Ipatasertib and Venclexta, Entinostat, Pembrolizumab, Eribulin Mesylate, Radium-223 dichloride, and others.
Table of Contents
|
1 |
HR-positive/HER2-negative Breast Cancer Report Introduction |
|
2 |
HR-positive/HER2-negative Breast Cancer Executive Summary |
|
3 |
HR-positive/HER2-negative Breast Cancer Overview |
|
4 |
HR-positive/HER2-negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment |
|
5 |
HR-positive/HER2-negative Breast Cancer Pipeline Therapeutics |
|
6 |
HR-positive/HER2-negative Breast Cancer Late Stage Products (Phase II/III) |
|
7 |
HR-positive/HER2-negative Breast Cancer Mid Stage Products (Phase II) |
|
8 |
HR-positive/HER2-negative Breast Cancer Early Stage Products (Phase I) |
|
9 |
HR-positive/HER2-negative Breast Cancer Preclinical Stage Products |
|
10 |
HR-positive/HER2-negative Breast Cancer Therapeutics Assessment |
|
11 |
HR-positive/HER2-negative Breast Cancer Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
HR-positive/HER2-negative Breast Cancer Key Companies |
|
14 |
HR-positive/HER2-negative Breast Cancer Key Products |
|
15 |
HR-positive/HER2-negative Breast Cancer Unmet Needs |
|
16 |
HR-positive/HER2-negative Breast Cancer Market Drivers and Barriers |
|
17 |
HR-positive/HER2-negative Breast Cancer Future Perspectives and Conclusion |
|
18 |
HR-positive/HER2-negative Breast Cancer Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Get a customized pipeline report @HR-positive/HER2-negative Breast Cancer Drugs Pipeline Report
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/